Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mucosis BV

This article was originally published in Start Up

Executive Summary

To date, the most common route of vaccination has been as an intramuscular injection, which raises a systemic immune response to the selected pathogen. Mucosal vaccines can trigger both a local and systemic immune response, limiting pathogen invasion at the point of entry. Mucosis BV is developing nasally and orally delivered mucosal vaccines to prevent and treat infectious and other diseases. Its technology is based on particles derived from inactivated Lactococcus lactis bacteria, which are used in cheese and buttermilk production and so are safe for human use.
Advertisement

Related Content

Start-Up Previews (12/2010)
Start-Up Previews (12/2010)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091910

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel